MRUS News and Press, Merus N.V. From 04/08/22

– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells – MCLA-129 significantly inhibits growth of a patient-derived EGFR exon20 insertion (exon20...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., P...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...

Merus press release (NASDAQ:MRUS): FY GAAP EPS of -$1.73 beats by $0.40. Revenue of $49.11M (+64.0% Y/Y) beats by $3.11M. For further details see: Merus GAAP EPS of -$1.73 beats by $0.40, revenue of $49.11M beats by $3.11M

As of February 2022, more than 100 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Clinical data updates planned for lead program Zeno in 1H22 and for petosemtamab (“MCLA-158”)...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific...

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group –  So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has ...

VANCOUVER – USA News Group – So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a decade long analysis . In just the fi...

Merus (NASDAQ:MRUS) presents clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients with HER2+ metastatic breast cancer (MBC) at the San Antonio Breast Cancer Symposium in San Antonio, Texas. The primary endpoint of clinical benefit rate (CBR) at 24 ...